Publication date: Jun 29, 2026
This study evaluated the efficacy and safety of a radiographic severity-stratified, all-oral short-course treatment regimen (STR) for multidrug /rifampicin-resistant tuberculosis (MDR/RR-TB) in China. Enrolled participants were randomised (2:1) to receive either an all-oral STR or an 18-month regimen based on the 2019 WHO guidelines as the control. The STR group was divided into three subgroups according to radiographic severity scores. The primary efficacy endpoint was a favourable treatment outcome up to 6 months after discontinuation. The primary safety endpoint was grade ≥3 adverse events (AEs) during the study period. A prespecified non-inferiority margin of
| Concepts | Keywords |
|---|---|
| China | bedaquiline |
| Discontinuation | multidrug-resistant tuberculosis |
| Month | non-inferiority trial |
| Prespecified | radiographic severity-stratified |
| Tuberculosis |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Rifampicin |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| drug | DRUGBANK | Bedaquiline |
| disease | MESH | multidrug-resistant tuberculosis |